Piracetam is an effective symptomatic treatment for some types of myoclonus in adults. To survey the efficacy and safety of piracetam in pediatric opsoclonusmyoclonus, we conducted an open, randomized, two-period, dose-ranging, doubleblind, crossover, clinical trial of five children comparing the antimyoclonic properties of oral piracetam to placebo. We devised and validated a new rating scale, specifically for pediatric opsoclonus-myoclonus. Two parents while blinded were able to identify the active phase by improvement in behavior, but another thought the behavior was worse. None of the patients showed improvement in myoclonus. The adult-equivalent dose of piracetam used in this study, which is threefold higher than that used in previous pediatric studies, was well tolerated and safe. We found our rating scale to be a reliable and useful tool for future studies of opsoclonus-myoclonus in children.
Piracetam (2-oxo-1-pyrrolidine acetamide, Nootropil) is the serendipitous prototype of a "nootropic" class of antimyoclonic drugs (1) . A reduction of myoclonus in progressive myoclonus epilepsy, posthypoxic myoclonus, and other myoclonic disorders has been reported in adults. Oral piracetam is rapidly absorbed, achieving peak plasma levels in 30 minutes with a halflife of about 5 hours before it is excreted unchanged in the urine (2) . Brain levels exceed plasma levels several hours after oral administration. Although piracetam is a cyclic derivative of ␥-aminobutyric acid, its action does not seem to be mediated by ␥-aminobutyric acid, and the mechanism of its antimyoclonic properties is unknown (3) .
Although piracetam is efficacious for certain types of myoclonus in adults, it has not been evaluated in the pediatric age group. With a median lethal dose of more than 10 g/kg (2) and a European reputation of being virtually nontoxic, it is ideal for study in the pediatric population. Children with opsoclonus-myoclonus, a putative autoimmune reaction to remote neuroblastoma or certain viral infections (4) , are especially in need of more effective treatment. Despite conventional immunotherapy, many are left with significant motor and cognitive impairment, and there are limited alternative treatments. This is a pilot study of piracetam for myoclonus in pediatric opsoclonus-myoclonus.
Although more than one evaluation scale has been developed to evaluate myoclonus in adults, they are not well suited for use in young children, who cannot comply with the required tasks. Previously, we designed and validated a pediatric myoclonus scale (5) , which we used in the present study to evaluate the clinical types of myoclonus. However, in the presence of ataxia, evaluation of action myoclonus can be difficult. As a more global measure of motor dysfunction in childhood opsoclonus-myoclonus, we now introduce a new scale that includes parameters affected by opsoclonus, myoclonus, tremor, and ataxia, the major motor manifestations of opsoclonus-myoclonus. This scale is well suited to scoring from videotapes, which is the documentation standard for drug trials in patients with movement disorders.
MATERIALS AND METHODS

Subjects
We recruited six children with opsoclonusmyoclonus through the National Pediatric Myoclonus Center. Consent for this Institutional Review Boardapproved study was obtained by the principle investigator. Patients had action-induced and spontaneous myoclonus. Subjects ranged in age from 2 to 6 years, and paraneoplastic and nonneoplastic etiologies were equally represented ( Table 1 ). The sixth and youngest subject was dropped from the study in the second phase when he refused piracetam because of its bitterness. He could not swallow pills, so the tablet had to be crushed. Despite whatever the parents used to try to camouflage the taste, he spit it out.
Establishing an Etiology
A thorough search for occult neuroblastoma, including urinary catecholamines, serum ferritin, neuronspecific enolase, paraneoplastic autoantibody panel (anti-Hu, antiRi, antiYo), body computed tomography scan, and 123 I-meta-iodobenzyl guanidine scan, was completed before enrollment in the study because the treatment of choice was removal of the tumor (4). Most often, however, referrals were made after tumor removal and immunotherapy.
Experimental Design
The drug trial was a double-blind, two-period, doseranging, crossover study separated by a drug washout. The enrollment of patients into the study was ongoing and sequential. The order of drug treatment (piracetam or placebo) was assigned randomly and coded. All patients were treated for 4 weeks with piracetam and with placebo, beginning with one and crossing over to the other after a 2-week washout. The first week was a dose-finding period (incremental dose), after which the patient stayed on the "best dose" for the following 2 weeks. The fourth week was a tapering period (decremental dose).
Drug Dosage and Administration
UCB supplied piracetam Secteur Pharmaceutical (Braine-L'Alleud, Belgium) in 800-mg caplets, the coating of which eases swallowing and prevents identification by bitter taste. The optimum dosage of piracetam was determined by gradual titration according to adverse and therapeutic effects in each patient. Although the dosage of piracetam in adults is not based on body weight, we scaled the pediatric dose accordingly, making the ceiling dose 400 mg/kg and the starting dose 80-130 mg/kg for a 5-kg and 45-kg child, respectively. The total daily starting dose was 2 g, which was increased stepwise to 8-10 g/d.
For small children, the scored caplet could be broken once or twice as necessary. We opted against the use of liquid formulations of piracetam so as not to introduce a variable in comparisons with adults taking pills. The liquid form is not very palatable for children and is associated with mild gastrointestinal symptoms.
Clinical Data Collection
Epidemiologic and historical data included patient's birth history, age of onset of myoclonus, chronologic and developmental age at start of study, and details of myoclonus, such as distribution and temporal pattern. Patients were examined once during periods 1 and 2. Patient vital signs were obtained at the end of week 1 and 3. Data as to sleeping patterns, personality changes, and drug compliance were also obtained. While they were still blinded, parents were asked to answer yes or no to each of a 10-item questionnaire. The responses were used to generate Table 2 .
Videotaping and Evaluation Scales
Videotapes were made by the research nurse practitioner according to a written set of instructions so that each item to be used for scoring was included. As a semiquantitative measure of myoclonus, we used the Myoclonus Evaluation Scale (MES), which we validated previously (5) . As a more global measure of motor dysfunction, we used the Opsoclonus-Myoclonus Scale (OMS) ( Table 3 ). Our trained research assistant, who had been included in the validation procedures mentioned in the next section and who was blinded to patient information, scored videotapes.
Validation of the Opsoclonus-Myoclonus Scale
We determined interrater reliability by a judge panel of two blinded observers (child neurologist and research assistant) independently scoring videotapes (one for each scale item) made at baseline before the start of the study. Correlations and paired t tests were used to analyze the data. Test-retest reliability was calculated by having the research assistant score the same five videotapes twice, and paired t tests were used to analyze the data. Having two neurologists review a few videotapes and determine whether the scale adequately gauged the patients' motor problems assessed face validity. Discriminate validity was assessed by having the research assistant score videotapes from 10 children with opsoclonus-myoclonus and the same number of normal children of similar age. These data were analyzed by an independent t test on each item.
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Laboratory Blood Tests
Complete blood count and metabolic panel (chem-20) were obtained before the study and four times during the study: twice on drug A and twice on drug B. The first blood drawing was at the end of week 1 and the second was in week 3.
Statistical Analysis
Scores on placebo and drug were compared statistically by two-tailed paired t tests as implemented on SAS, a statistical analysis computer software program for the PC (6) .
RESULTS
Efficacy
Blinded parents reported subjective responses. Of five children with opsoclonus-myoclonus, blinded parents of two correctly identified the active drug phase because of isolated improvement in behavior and attention span, not effects on myoclonus (Table 2) . Another parent, however, reported aggressive behavior with the drug.
Objective responses were scored from videotapes. Piracetam had no significant effect on MES scores compared to placebo (Table 4) .
Performance on the OMS was analyzed both by individual components and by total scores (Table 5 ). There were no significant drug effects.
Safety
No abnormalities were found in vital signs, blood cell counts, or blood chemistries. No one withdrew The MES (action-induced, spontaneous, sensory-evoked) as scored by a blinded observer from videotapes. For each of the three categories of the scale (frequency, distribution, intensity), the scorer assigned a score of 0 to 4 (0, normal; 1, rare myoclonic jerk; 2, some/occasional myoclonus; 3, many/intermittent myoclonic jerks; 4, continuous myoclonus). Because there was no consistent sensory-evoked myoclonus, scores for it were dropped from the scale. The maximum abnormality (total for spontaneous myoclonus plus total for action myoclonus) was a score of 24. Data are expressed as the mean ± SEM, N = 5.
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from the study because of drug side effects. All but one of the children reached the maximum dose studied.
Validation of Opsoclonus-Myoclonus Scale
We found the OMS to be reliable and easy to use. Interrater reliability (0.90 correlation) and test-retest reliability (0.87 correlation) were high. Discriminate validity for patients versus controls was also statistically significant (p = 0.001).
DISCUSSION
Implications for Opsoclonus-Myoclonus and Subcortical Myoclonus
The reason that piracetam was not efficacious against myoclonus in our children with opsoclonusmyoclonus may be because the myoclonus is subcortical in origin, as first suggested by Kinsbourne (7) . An electrophysiologic study in three adults with opsoclonus-myoclonus found no cortical correlate using backaveraging (8) . Most adults with cortical myoclonus benefit from piracetam at a dose of 16.8-24 g/d (9-11), but it is not effective (9) or less effective (11) for subcortical myoclonus in open-label studies. However, given the lack of controlled trials of piracetam in children and in subcortical myoclonus of various etiologic subtypes, we believed a pilot study in opsoclonusmyoclonus was worth doing. Although a larger sample size conceivably might have identified responders, the lack of motor improvement in five consecutive children was not deemed sufficiently promising to warrant further study.
Perhaps piracetam is ineffective against subcortical myoclonus because it acts selectively on cortical mechanisms (12) . However, correlation between elec-trophysiologic and clinical responses to piracetam has not been a uniform finding (11) , especially during monotherapy (13) . In one study, 25% of adults with cortical myoclonus did not improve with piracetam (13) .
Monotherapy may have put our patients at a disadvantage if a synergistic effect with antiepileptic drugs explains greater piracetam efficacy in cortical myoclonus (14) . Piracetam monotherapy had no effect on myoclonus in one study (13) , but was effective in two others (10, 11) .
An argument could also be made for pharmacokinetic differences affecting regional distribution of piracetam. In the rat, the concentration of piracetam 4 hours after an oral dose of 500 mg/kg was lowest in the pons-medulla and highest in cortex, but the differences between any brain region, including other subcortical structures, were less than 40% (2) . The significance of these differences and their occurrence in humans is unknown.
Safety of Piracetam in Children
We found no adverse effects of piracetam on blood parameters. In a piracetam study of adults with myoclonus, two of 60 patients developed reversible hematologic abnormalities (thrombocytopenia or leukopenia), which were attributed to interactions with antiepileptic drugs (11) . No abnormalities were found in 24 patients in another study (10) .
We identified no pediatric studies of the adultequivalent piracetam dose used in our study. Low doses of 3.3 g/d, or approximately 80-170 mg/kg, have been used safely in hundreds of school-aged children for dyslexia (15) (16) (17) (18) (19) (20) , attention deficit disorder (21), nocturnal enuresis (22) , sensorineural hearing loss (23) , and to study brain electrical potentials in normal children (24) . Our study supports the use of 2.5-3 times higher doses of piracetam in studies of children.
Suggestions for Future Pediatric Studies
A smaller dose preparation will be necessary for studies of piracetam in young children old enough to swallow pills. The liquid preparation, which has been used in all trials to date, is not palatable to youngsters and produces gastrointestinal disturbances. Given the lack of side effects, higher doses could be entertained. Also, the study of putative cognitive or behavioral properties of piracetam would require a different paradigm than ours, which focused on motor responses. Myoclonus is an important problem in infants and toddlers, who deserve the benefit of therapeutic trials. A study of piracetam for cortical myoclonus of pediatric onset is in progress at our center. Data are means ± SEM, N = 5. See Table 3 for an explanation of test items.
